Desley van Zoggel

Chapter 5 78 Table 1. Baseline and primary tumour characteristics Gender Female Male Age at resection Median (IQR) ASA I-II III Tumour stage pT1/T2 pT3/T4 Nodal stage pN0 pN1/N2 Neoadjuvant radiotherapy None Short-course radiotherapy Full-course (chemo)radiotherapy Type of surgery TEM Rectosigmoid resection/LAR Abdominoperineal resection Adjuvant therapy None Adjuvant chemotherapy Values in parentheses are percentages unless otherwise specified. Numbers do not always add up to 349 due to missing values (ASA n=22; tumour stage n=6; nodal stage n=9). Overall survival The 3-year OS rate in all patients was 53 percent (median 39.7 months), and 54 percent, 65 percent, and 39 percent (median 43.0, 40.7, and 20.8 months) in patients without metastases, with a history of metastases, and with synchronous metastases, respectively (P = 0.129; Figure 1A). When comparing groups separately, no significant difference in OS was observed in patients without metastases versus those with a history of metastases (P = 0.592), without metastases versus synchronous metastases (P = 0.071), and a history of metastases versus synchronous metastases (P = 0.091). A comparison between patients with synchronous metastases and those without synchronous metastases showed a trend towards a significant difference in the 3- year OS (39 percent versus 56 percent respectively, P = 0.051).